Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lisziewicz, Julianna ^a   Bakare, Nyasha ^b   Calarota, Sandra A ^b   Bánhegyi, Dénes ^c   Szlávik, János ^c   Újhelyi, Eszter ^c   Toke, Eniko R ^a   Molnár, Levente ^a   Lisziewicz, Zsolt ^a   Autran, Brigitte ^d   Lori, Franco ^b  

^a Genetic Immunity Budapest Hungary and Genetic Immunity Inc   (United States)

^b The Research Institute for Genetic and Human Therapy   (United States)

^c Szent Laszlo Hospital   (Hungary)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ZIDOVUDINE; GAMMA INTERFERON; VIRUS ANTIGEN;

ADULT; ARTICLE; CELL EXPANSION; CELL POPULATION; CLINICAL ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREACTIVITY; INDUCED HYPOTHERMIA; LANGERHANS CELL; LOW BACK PAIN; LOW DRUG DOSE; LYMPHOCYTE COUNT; MACULAR ERYTHEMA; MALE; MEMORY T LYMPHOCYTE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; SKIN ALLERGY; TRANSDERMAL PATCH; ADOLESCENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; EPIDERMIS; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPH NODE; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; AIDS VACCINES; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPIDERMIS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LANGERHANS CELLS; LYMPH NODES; MALE; MIDDLE AGED;

EID: 84860745751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035416     Document Type: Article

References (33)

1. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, et al. (2009) Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late nitiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49: 1570-1578.
2. Haase AT, (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5: 783-792.
3. Shen L, Siliciano RF, (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immun 122: 22-28.
4. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, et al. (2011) A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 203 (7): 894-897.
5. Dinosoa JB, Kima SY, Wiegandc AM, Palmerc SE, Ganged SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-9408.
6. Gandhi RT, Zheng L, Bosch RZ, Chan ES, Margolis DM, et al. (2011) The effect of Raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7: 1-11.
7. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, et al. (2010) Short-course Raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50: 912-919.
8. Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, et al. (2011) HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117: 5391-5402.
9. Somogyi E, Xu J, Gudics A, Toth J, Kovács A, et al. (2011) A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 29: 744-753.
10. Toke ER, Lorincz O, Somogyi E, Lisziewicz J, (2010) Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm 392: 261-267.
11. Lorincz O, Toke ER, Somogyi E, Horkay F, Chandran PL, et al. (2011) Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine Nanotechnology, Biology and Medicine doi:10.1016/j.nano.2011.07.013.
12. Lisziewicz J, Gabrilovich DI, Varga G, Xu J, Greenberg PD, et al. (2001) Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol 75: 7621-7628.
13. Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, et al. (2005) DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 124: 160-169.
14. Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, et al. (2007) HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366: 197-211.
15. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, et al. (2005) Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19: 35-43.
16. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation and maintenance. Annu Rev Immunol 22:7 45-763.
17. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+T cells. Blood 107: 4781-4789.
18. Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, et al. (2006) Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood 107: 1427-1433.
19. Schellens IMM, Borghans JAM, Jansen CA, De Cuyper IM, Geskus RB, et al. (2008) Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoSOne 3: 1-8.
20. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, et al. (2005) Durable human memory T cells quantifiable by Cultured Enzyme-Linked Immunospot Assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 175: 5675-5680.
21. Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, et al. (2008) HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180: 5907-5915.
22. Flanagan KL, Lee EAM, Gravenor MB, Reece WHH, Urban BC, et al. (2001) Unique T cell effector functions elicited by plasmodium falciparum epitopes in malaria-exposed africans tested by three T cell assays. J Immunol 167: 4729-4737.
23. Godkin AJ, Thomas HC, Openshaw PJ, (2002) Evolution of epitope-specific memory CD4 T cells after clearance of Hepatitis C virus. J Immunol 169: 2210-2214.
24. Matzinger P, (2002) The danger model: a renewed sense of self. Science 296: 301-305.
25. Holzmann S, Tripp CH, Schmuth M, Janke K, Franz K, et al. (2004) A Model System Using Tape Stripping for Characterization of Langerhans Cell-Precursors In Vivo. J Invest Dermatol 122: 1165 -1174.
26. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, et al. (2006) Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36: 2585-2594.
27. Notermans DW, de Wolf F, Oudshoorn P, Cuijpers HT, Pirillo M, et al. (2000) Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses 16: 1507-1517.
28. Casazza JP, Betts MR, Picker LJ, Koup RA, (2001) Decay kinetics of Human Immunodeficiency Virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 75: 6508-6516.
29. Koup RA, Safrit JT, Cao Y, Andrews CA, MLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
30. Natz E, Lisziewicz J, (2011) Rational design of formulated DNA vaccine: The DermaVir approach. In: Thalhamer J, Weiss R, Scheiblhofer S, editors. Gene vaccines SpringerWienNew York pp. 127-143.
31. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
32. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel. JAMA 304: 321-333.
33. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, et al. (2008) Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol 180: 7907-7918.